[18F]FPIA PET/CT Imaging in Patients With Solid Tumours

Cancer Clinical Trial

— [18F]FPIA  

Official title:

An Investigation of Short-chain Fatty Acid Uptake in Solid Tumours as Assessed by [18F]Fluoropivalate Positron Emission Tomography and Its Relationship With Tumour Proliferation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04717674
• Other study ID #: 135083
• Status: Recruiting
• Phase: Phase 2
• Start date: December 7, 2021
• Est. completion date: October 2024

Study information

• Verified date: October 2023
• Source: University College, London
• Contact: Laura McLeavy
• Phone: 0203 313 3720
• Email: ncita.fpia[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will be a phase 2, open-label study in patients with solid tumours to explore the relationship between short-chain fatty acid uptake using [18F]FPIA PET/CT and tumour proliferation

Description:

Cancers have increased energy demands to allow for their rapid growth compared to healthy cells. Glucose is the main source of energy for many cells in the body, and clinicians routinely use a scan which looks at glucose metabolism to assess if cancer treatment is working. However, some cancer cells can create energy to survive and grow in a different way, using fatty acids. In this study, the investigators are using a PET/CT scan to look at a variety of cancer types to see which cancers use fatty acids for energy and if this can be measured. The PET/CT scan will be carried out twice on 2 separate visits so that the investigators can check that both scans give the same result. The investigators will also carry out special tests on the tumour tissue taken during routine cancer surgery. These tests will look for specific substances in the cancer cells that are related to cancer biology and growth. The investigators will then compare the results from the surgical tissue to the results of the scan to see if there is a relationship between them. The study will look at 21 patients with solid tumours conducted in 4 NCITA accredited centres, which have different strengths in recruiting specific patient/tumour-type cohorts. Each patient will have two scan visits (between 2-15 days apart) prior to any new treatment starting to check that the scan measurements are repeatable.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 21
• Est. completion date: October 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with radiological evidence of solid primary or metastatic target tumour

lesions and the following characteristics will be recruited:

1. Age =18 years of age

2. Radiologically confirmed tumour size =15mm (at least one lesion must be extra-hepatic)

3. The participant is due to undergo surgery within 3 months of the first [18F]FPIA PET/CT

4. There is time to complete the two research PET studies without any delay to surgery

5. WHO performance status 0 -2

6. If female, the participant is either post-menopausal (>1 year), or surgically sterilised (has had a documented bilateral oophorectomy and/or documented hysterectomy, >2 years), or if of childbearing potential, must have a negative urine pregnancy test within 2 hours prior to injection of imaging agent

7. The participant is able and willing to comply with study procedures, and signed and dated informed consent is obtained.

8. eGFR of =30 within 3 months of [18F]FPIA injection.

9. The participant is not scheduled to start cancer treatment (e.g. chemotherapy, radiotherapy, biological therapy or immunotherapy) within the study scanning period.

Exclusion Criteria:

• 1. The participant has received chemotherapy, immunotherapy, biologic therapy or investigational therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of [18F]FPIA injection or is due neoadjuvant therapy between the PET and surgery.

2. The participant is pregnant or lactating. 3. The participant is scheduled to have a nuclear medicine or contrast scan within 24 hours before the administration of [18F]FPIA.

4. Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure.

Related Conditions & MeSH terms

• Cancer
• Tumor, Solid

Intervention

Drug:
• [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)
[18F]FPIA radiotracer administration

Procedure:
• PET/CT
PET/CT scan

Locations

Country	Name	City	State
United Kingdom	Guy's & St. Thomas' NHS Foundation Trust	London
United Kingdom	Imperial College Healthcare NHS Trust	London
United Kingdom	The Royal Marsden NHS Foundation Trust	London

Sponsors (4)

Lead Sponsor	Collaborator
University College, London	Cancer Research UK, Imperial College London, National Cancer Imaging Translational Accelerator

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To explore the relationship between [18F]FPIA tumour uptake and histological markers of tumour metabolism.	Graphical and tabular description of the relationship of [18F]FPIA uptake with biological markers including pan-mitochondrial markers (succinate dehydrogenase [SDHA], citrate synthase), and fatty acid oxidation enzymes (carnitine palmitoyltransferase I/carnitine acyltransferase I [CPT1/CAT1], carnitine-acylcarnitine translocase [CACT], SLC22A2, SLC22A5, and SLC25A20), evaluated by IHC	6 months
Primary	The relationship between [18F]FPIA uptake and percent positive tumour cells reported as counts defined per area from whole section immunohistochemistry for PHH3.	To explore the relationship between short-chain fatty acid uptake using [18F]FPIA PET/CT and tumour proliferation in patients with solid tumours.	6 months
Secondary	Estimation of SUVmax of target lesions at 30 minutes and 60 min.	The SUVmax of the target lesions will be estimated for both timepoints (i.e. 30 min and 60 min) in order to assess changes in this measurand at the two time points.	60 min
Secondary	Estimation of tumour-to-background ratio of target lesions at 30 minutes and 60 min.	The tumour-to-background ratio of the target lesions will be estimated for both timepoints (i.e. 30 min and 60 min), in order to assess changes in this measurand at the two time points.	60 min
Secondary	Graphical presentation and reliability of repeat semi-quantitative measure (SUV) of target lesions between two PET scans for each time point (30 min and 60 min). Bland Altman and ICC will be presented.	To assess the repeatability of the two [18F]FPIA PET scans, as this can impact the primary end point. The two [18F]FPIA PET scans will be 2-15 days apart, and each will consist of two imaging timepoints (30 minutes and 60 minutes).	15 days
Secondary	Graphical presentation of [18F]FPIA uptake and whole section immunohistochemistry for Ki-67 and mitotic count (mitoses per mm2) assessed on hematoxylin and eosin (H&E) sections. Pearson's correlation coefficient will be reported.	To explore the relationship between [18F]FPIA PET/CT and other known tumour proliferation markers	6 months